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mtDNA mutagenesis in somatic stem cells leads to
their dysfunction and to progeria in mouse. The
mechanism was proposed to involve modification
of reactive oxygen species (ROS)/redox signaling.
We studied the effect of mtDNA mutagenesis on
reprogramming and stemness of pluripotent stem
cells (PSCs) and show that PSCs select against spe-
cific mtDNA mutations, mimicking germline and
promoting mtDNA integrity despite their glycolytic
metabolism. Furthermore, mtDNA mutagenesis is
associated with an increase in mitochondrial H2O2,
reduced PSC reprogramming efficiency, and self-
renewal. Mitochondria-targeted ubiquinone, MitoQ,
and N-acetyl-L-cysteine efficiently rescued these de-
fects, indicating that both reprogramming efficiency
and stemness are modified by mitochondrial ROS.
The redox sensitivity, however, rendered PSCs and
especially neural stem cells sensitive to MitoQ
toxicity. Our results imply that stem cell compart-
ment warrants special attention when the safety of
new antioxidants is assessed and point to an essen-
tial role for mitochondrial redox signaling inmaintain-
ing normal stem cell function.INTRODUCTION
Genomic integrity is crucial for stem cells, to enable tissue main-
tenance. Mutations affecting nuclear genomic DNA repair lead to
somatic stem cell (SSC) dysfunction and premature aging:
mousemodels with genomic DNA repair defects show progeroid
phenotypes (Barlow et al., 1996; de Boer et al., 2002; Gu et al.,
1997). mtDNA integrity is also required for proper stem cell func-
tion: ‘‘mtDNA mutator’’ mice, which accumulate random mtDNA
mutations in all tissues, including SSCs, develop progeria, with
gray hair, alopecia, osteoporosis, general wasting, anemia,1614 Cell Reports 11, 1614–1624, June 16, 2015 ª2015 The Authorsreduced fertility, and shortened lifespan (Ameur et al., 2011; Ku-
joth et al., 2005; Trifunovic et al., 2004). These mice have a pro-
gressive dysfunction of hematopoietic, neural, and intestinal pro-
genitor cells, starting early during embryogenesis (Ahlqvist et al.,
2012; Chen et al., 2009; Fox et al., 2012; Norddahl et al., 2011);
however, the first progeric symptomof thesemice, anemia,man-
ifests only after 6 months of age. The embryonal SSC defect can
be rescued by treatment with N-acetyl-L-cysteine (NAC) (Ahlqv-
ist et al., 2012), suggesting a redox component in the pathology.
These data show that hematopoietic and neural progenitors are
sensitive to mtDNAmutagenesis and dysfunction, but the mech-
anisms remain unclear.
Somatic stem/progenitor cell metabolism mostly relies on
glycolytic activity, and mitochondrial respiration typically gradu-
ally increases upon differentiation (Suda et al., 2011). However,
mitochondria are present and active in stem cells even though
their contribution to the cellular ATP demand is minor (Zhang
et al., 2011). This downregulation of mitochondrial ATP produc-
tion may leave the mitochondria under conditions of high pro-
ton-motive force and a reduced respiratory chain (RC), which
favors mitochondrial reactive oxygen species (ROS) production
(Chouchani et al., 2014; Murphy, 2009). ROS are potent
signaling molecules; for example, they are known to drive
HPCs to proliferate and to contribute to erythroid differentiation
(Suda et al., 2011). The consequences of primary mitochondrial
dysfunction for SSC and progenitor compartments are, howev-
er, poorly understood. In mtDNA mutator mice, random amino
acid changes accumulate in RC complexes, including com-
plexes CI and CIII—the major producers of mitochondrial
ROS. Changes in ROS levels have been found in some tissues
in aged mutators (Logan et al., 2014), but little signs of oxidative
damage were apparent (Kolesar et al., 2014; Trifunovic et al.,
2005), indirectly suggesting that modified ROS signaling, not
oxidative stress, mediate SSC dysfunction and progeria in mu-
tator mice.
We report here that mtDNA mutagenesis increases mitochon-
drial H2O2 in pluripotent stem cells (PSCs) in vitro, resulting in
modification of reprogramming, pluripotency, and stem cell ho-
meostasis. We show that both induced PSCs (iPSCs) and
SSCs are especially sensitive to ROS and also to antioxidants
NAC and mitochondria-targeted ubiquinone (MitoQ), which
both improved stem cell function. However, MitoQ also showed
dose-dependent toxicity specific for neural stem cells (NSCs)
and iPSCs. These data indicate that long-term treatment
trials in animal models, with special focus on the stem cell
compartment, are warranted when assessing safety of new
antioxidants.
RESULTS
Antioxidants NAC and MitoQ Rescue Reprogramming
Defect Associated with mtDNA Mutagenesis
Mouse embryonic fibroblast (MEF) cultures were established
from E13.5–14.5 mutator and WT embryos, subsets of which
were supplemented with NAC or MitoQ during the whole
embryogenesis and post-harvest in vitro culture. The different
genotypes showed no difference in proliferation, clonality,
viability, or transfection efficiency, and the antioxidant treat-
ments had no effect on these (Figure S1). However, when
reprogramming the MEFs to pluripotency, 10-fold more col-
onies arose from the WTs than from mutator MEFs (Figure 1A).
The decreased reprogramming efficiency of mutators was
significantly improved by the two antioxidants with different
mechanisms of action: NAC increases cellular glutathione and
consequently redox-buffer capacity of the cell, whereas MitoQ,
a modified ubiquinone, is targeted to accumulate within mito-
chondria (Kelso et al., 2001). NAC increased the number of mu-
tator colonies 4-fold, and the effect of MitoQ was 10-fold, the
latter rescuing the efficiency to WT level. Neither of the antiox-
idants had a significant effect on the reprogramming of WT
MEFs (Figure 1A). Culture and reprogramming in 4% oxygen
improved reprogramming efficiency similarly for both geno-
types (Figure 1B).
To directly assess whether mtDNA mutagenesis affected
mitochondrial ROS production in iPSCs, we utilized a mito-
chondria-targeted probe MitoB: arylboronic acid conjugated to
triphenylphosphonium ion (TPP) (Cocheme´ et al., 2012). The
lipophilic TPP mediates rapid uptake of MitoB into cells and
accumulation in mitochondria, where MitoB reacts with H2O2
and forms a phenol-derivative MitoP. MitoP/MitoB ratio can be
measured by ratiometric mass spectrometry and reflects the
mitochondrial H2O2 level (Cocheme´ et al., 2012). Mutator iPSCs
showed an increase in the MitoP/MitoB ratio, consistent with an
increase in mitochondrial H2O2 (Figure 1C).
Neither mtDNA mutagenesis nor antioxidant treatment
affected expression of the pluripotency markers in the estab-
lished iPSC lines (Figures S1F and S1G). The tet-inducible-pro-
moter-driven reprogramming transgenes were silenced in all
the clones analyzed (Figure S1H), and early passage iPSC clones
exhibited normal karyotypes (Figure S1I). Upon suspension cul-
ture and withdrawal of LIF (leukemia inhibitory factor), all tested
clones produced embryoid bodies (WT: n = 6; Mut: n = 6), and
when injected into nude mice, all tested clones (WT: n = 3;
Mut: n = 6) generated teratomas with cell types from all three
germ layers present in them (Figure S1J). These results imply
that mtDNA mutagenesis increases mitochondrial H2O2 and
that mitochondrial ROS inhibit nuclear reprogramming, which
can be rescued by antioxidants.CeMitochondrial Antioxidant MitoQ: Low Concentrations
Improve whereas Moderate Concentrations Impair
Self-Renewal of PSCs
Clonal capacity, i.e., ability of a single stem cell to generate a
new stem cell clone, is considered a measure of stemness. The
clonality of mutator iPSCs was decreased to one-fourth of WTs.
This self-renewal defect was partially rescued by NAC (100 mM)
and low concentration of MitoQ (10 nM). NAC treatment had no
significant effect on WT cells (Figures 1D and 1E). However,
100 nM MitoQ—the concentration successfully used during MEF
reprogramming—instead of improving mutators, had a detri-
mental effect on WT clonality (Figures 1D and 1E), whereas NAC
even in10-foldconcentration (1mM) improvedself-renewalofmu-
tator iPSCs and showed no adverse effects on WTs (Figures 1D
and1E).These results indicate thatMitoQhasanarrowtherapeutic
windowand can be harmful to stemcells at higher concentrations.
The self-renewal ability was reflected in the embryonic stem
cell marker SSEA1 (stage-specific embryonic antigen-1) expres-
sion: a significantly larger population of SSEA1-negative cells
existed in mutator iPSCs. MitoQ treatment dose dependently
increased the proportion of SSEA1-negative cells, as a possible
sign of impaired stemness of the iPSC (Figures 1F and 1G). This
was not associated with increased cell death (Figure 1H).
Our results show that mtDNA mutagenesis reduces iPSC
clonal ability, a measure of stemness. NAC rescues this defect
without apparent toxicity. Mitochondria-targeted MitoQ also
effectively rescues the defect at low concentrations but is dele-
terious for iPSC self-renewal with concentrations that improved
fibroblast reprogramming.
Mutator iPSCs Show a ROS-Independent Growth Defect
Mutator MEFs showed no difference to WT growth (Figures S1A
and S1B), but the mutator iPSCs manifested a severe growth
defect, with doubling times around 24 hr for mutators and
16 hr for WT cells (Figures 2A and 2B). Also, mutator embryoid
bodies (EBs) grew slowly (Figure 2C). The proportion of prolifer-
ating cells was similar between mutator and WT cultures when
analyzed by BrdU incorporation and FACS (Figure 2D), and
apoptosis was not increased (annexin V and propidium iodide
staining; FACS analysis; Figure 2E). NAC or MitoQ had no effect
on the slow growth. These results indicate that mtDNAmutagen-
esis delays stem cell growth by a redox-independent manner
without inducing cell death.
Differential Response of Somatic Progenitor Cells to
Antioxidants
The adverse effect of MitoQ on iPSCs at a relatively low concen-
tration range prompted us to investigate the effect of MitoQ
in vivo to somatic progenitor cells. We extracted NSCs from
the brain and hematopoietic progenitors (HPCs) from the liver
of E14.5–15.5 embryos treated either with MitoQ (0.75 mg/ml)
or as control an equivalent dose of lipophilic decyl-TPP (dTPP)
without ubiquinone (0.48 mg/ml). These cell types previously
showed either an abnormal differentiation pattern (HPCs) or a
self-renewal defect (NSCs) in mutators, which was rescued by
NAC (Ahlqvist et al., 2012). MitoQ, but not dTPP, rescued the
abnormal proportions of embryonal HPCs in mutator embryos,
replicating our previous results with NAC (Figures 3A and 3B).ll Reports 11, 1614–1624, June 16, 2015 ª2015 The Authors 1615
Figure 1. Mitochondrial ROS Reduce Reprogramming Efficiency and Stemness of iPSCs, Ameliorated by Antioxidants NAC and MitoQ
(A) Reprogramming efficiency. Numbers indicate the amount of alkaline phosphatase (AP)-positive colonies on day 14 after induction.WT versusMut: p < 0.0001;
Mut NAC (0.1 mM): p < 0.0001; Mut MitoQ (100 nM): p < 0.0001.
(B) Reprogramming in low oxygen (4%). Fold increase: WT: 2.9 ± 0.23; Mut: 3.0 ± 0.39.
(C) Intra-mitochondrial production of H2O2. The iPSCswere fedMitoB, which reactswith H2O2 and formsMitoP.Mass spectrometric analysis of MitoP andMitoB,
expressed as ratio of MitoP/MitoB, represents mitochondrial H2O2 levels; p = 0.0265.
(D) Clonality of mutator and WT iPSCs. Figure shows AP-stained plates 7 days after clonal plating. The scale bars represent 10 mm.
(legend continued on next page)
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Figure 2. Severe Non-redox-Linked Growth Defect but No Increase in Apoptosis in Mutator iPSCs
(A) Growth of mutator andWT iPSCs. Appearance of clones in phase-contrast microscopy is shown on the left. The scale bars represent 200 mm. Number of cells
is shown on the right.
(B) Doubling time of mutator and WT iPSCs with and without antioxidant treatments. WT versus Mut: p < 0.0001.
(C) Growth of embryoid bodies during early stages of differentiation. The scale bars represent 200 mm.
(D) Proliferating cells (BrdU incorporation; FACS analysis).
(E) Apoptosis assay (annexin V and PI staining and FACS analysis).
Data represent one (C), two (D and E), or three (B) independent experiments and are represented as mean ± SEM.However, neurospheres extracted from the same MitoQ-treated
embryos showed abnormal morphology (Figure 3C) and an
increase in apoptosis (Figure 3D). These were not found in
dTPP-treated embryos. Consequently, we were not able to
establish stable neurosphere cultures from the MitoQ-treated
embryos. Concentration-dependent toxicity was also evident
when previously untreated neurosphere cultures were subjected
to MitoQ in vitro: 10 nM MitoQ maintained normal self-renewal
and viability, whereas already 50 nM MitoQ induced apoptosis
(Figures 3C and 3D) and reduced the proportion of self-renewing
cells (Figure 3E). NAC treatment was not toxic to NSCs even at a
high concentration (Figures 3C–3E). Neuronal cells differentiated
from NCSs (mixed cultures of Tuj-1+ neurons and GFAP+ astro-
cytes with increasing mtDNA copy number indicating mitochon-
drial maturation; Figure S2) tolerated higher concentrations of
MitoQ (Figure 3F). However, MitoQ was still toxic to immature
neuronal cultures at 250 nM—aconcentration that did not induce
cell death inMEFs or iPSCs (Figures 3F, 3G, and 1H).MEFs toler-
ated antioxidants extremely well, as neither 1 mM MitoQ nor
2mMNAC induced apoptosis in MEFs (Figure 3G). These results(E) Quantification of the colonies from (D). ***p < 0.0001.
(F) SSEA-1 expression analyzed by FACS. FACS plots of untreated cells (left) an
SSEA1-negative population.
(G) Quantification of the SSEA1-negative cells from the FACS plots. WT versus M
(H) Apoptosis (annexin V staining and FACS analysis) in iPSCs with and without
Data represent one (B and C), two (A, E, G, and H), or four (A and E untreated c
Figure S1 for characterization of MEFs and iPSCs.
Ceshow that antioxidants have cell-type-specific effects and sug-
gest that mitochondria-targeted MitoQ can be toxic to specific
cell types with NSCs being especially vulnerable.
Mutator iPSCs Show a Combined RC Defect and Are
Highly Glycolytic
In western blot analysis, mutator iPSCs showed a severe
decrease of complex IV (cytochrome c oxidase [COX]) protein
amount (Figure 4A), and complexes I and III (CI and CIII) were
moderately decreased, indicating a combined RC defect (Fig-
ures 4A and 4B). The antioxidant treatments increased these
protein amounts about 2-fold, rescuing the amounts of CI
(NAC-treated) and CIII (MitoQ-treated) and inducing COX to
20% of WT mean (Figure 4B). A histochemical COX activity
assay indicated low activity in mutators compared to WT cells
(Figure 4C). These results showed that antioxidants can improve
RC protein amounts in stem cells with mtDNA mutations,
implying active ROS regulation of RC protein levels.
We further analyzed the cellular metabolism, both cell respira-
tion and glycolysis, by Seahorse XFe analyzer. Mutator iPSCsd MitoQ-treated WT cells (10 nM, right) are shown. Yellow shading indicates
ut: p = 0.0029; WT 100 nM MitoQ: p < 0.0001.
antioxidant treatment.
ells) independent experiments and are represented as mean ± SEM. See also
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Figure 3. Contrary Effects of MitoQ in
Somatic Stem Cells In Vivo and In Vitro
(A) Beneficial effect ofMitoQ inHSCsextracted from
E13.5 embryos in vivo. The bars represent the
amount of basophilic erythroblasts (CD71+Ter119+)
in fetal liver. WT versusMut: p = 0.0034; MutMitoQ:
p = 0.0025.
(B) The amount of the more-mature orthochro-
matophilic erythroblasts (Ter119+ CD71low). WT
versus Mut: p = 0.0010; Mut MitoQ: p = 0.0085.
(C) Neurospheres extracted from the same em-
bryos. The mothers were drinking either water
or water spiked with 1 mg/ml NAC, 0.75 mg/ml
MitoQ, or 0.48 mg/ml dTPP throughout the preg-
nancies, and the initial cultures were either sup-
plemented with 100 mM NAC, 50 nM MitoQ, or left
untreated. Untreated NSC cultures were later
subjected to MitoQ. The scale bars represent
50 mm.
(D) Apoptosis (annexin V staining and FACS
analysis) in the NSC cultures with and without
antioxidant treatment. In vivo MitoQ treatment:
p < 0.0001; in vitro 10 nM versus 50 nM MitoQ:
p < 0.0001.
(E) Self-renewing cells in untreated and antioxi-
dant-treated NSC cultures. 10 nM versus 50 nM
MitoQ: p = 0.0067.
(F) Apoptosis in differentiated neurons. 50 nM
versus 250 nM MitoQ: p = 0.05.
(G) Apoptosis in MEFs.
Data represent one (A and B) or two (D–G) inde-
pendent experiments and are represented as
mean ± SEM. See also Figure S2 for character-
ization of the differentiated neuronal cultures.showed low cellular respiration (Figure 4D), and when kept in
ample glucose, they used their maximal glycolytic capacity (Fig-
ure 4E), whereasWT cells utilized both respiration and glycolysis
(Figures 4D and 4E). When cell respiration (oxygen consumption
rate [OCR]) was calculated against glycolytic activity (extracel-
lular acidification rate [ECAR]), mutators showed a strong shift
toward glycolytic metabolism (Figure 4F). Both antioxidant treat-
ments increased respiration in mutator iPSCs and normalized
the OCR/ECAR ratio (Figures 4F and 4G) but had no significant
effect on WT cells. In mutator MEFs, glycolytic activity was
also slightly increased, although basal respiration remained at
WT level (Figures S3A–S3C). The strong dependence of the
mutator cells on glycolytic metabolism was further supported
by their complete dependence on glucose: a clear reduction in
growth was evident in mutators when reducing glucose concen-
tration to one-third of the original (4.5 g/l), and complete with-
drawal of glucose almost completely arrested their growth
(Figure S3D). WT cells showed a growth defect only upon com-
plete withdrawal of glucose (Figure S3D). Mutator growth was1618 Cell Reports 11, 1614–1624, June 16, 2015 ª2015 The Authorsalso inhibited by non-fermentable carbon
source, galactose, which well supported
WT cell growth (Figure S3D). Both WT
and mutator cells responded to glucose
addition by decreasing respiration and
increasing glycolytic activity, but muta-tors induced anaerobic glycolysis more than WT cells (Figures
S3E and S3F).
These data show that the combined RC defect in mutator
iPSCs is partially ROS dependent and rescued by antioxidants.
The metabolism of mutator iPSCs strongly favors glycolysis,
whereas the antioxidant treatments switch it to the more-typical
iPSC mode, using both respiration and glycolysis. These data
point to a role for ROS in stem cell metabolic shift, requiring a
delicate balance of oxidative phosphorylation and anaerobic
glycolytic activity.
iPSCs Show Selection against mtDNA Mutations
To clarify whether mtDNA mutation loads and profiles could
contribute to the observed iPSC findings, we used next-genera-
tion sequencing and sequenced the whole mitochondrial
genome of the parental MEFs and iPSCs of early and late pas-
sages. We further differentiated the iPSCs to fibroblast-like cells
(secondary fibroblasts) and analyzed their mutation frequencies.
Three to six clones were sequenced per group, and the average
Figure 4. Mutator iPSCs Manifest a Severe Combined Respiratory Chain Deficiency and Are Extremely Glycolytic
(A) Analysis of respiratory chain complexes by western blot.
(B) Quantification of western analysis. Complex I (NDUFA9): p = 0.0113; complex II (70 kD), complex III (UQCRC2): p < 0.0001; complex IV (COX1): p < 0.0001;
complexV (ATP5A). In the treated cells, CI (NAC; p = 0.000648), CIII (MitoQ; p = 0.00381), and CIV (NAC/MitoQ; p < 0.0001) levels were increased. The protein
amounts were normalized against TOM20, a mitochondrial outer membrane protein.
(C) Cytochrome c oxidase (COX) activity staining (brown). The scale bars represent 200 mm.
(D) Oxygen consumption rate (OCR) in Mito stress test. Basal and maximal respiration and ATP production: p < 0.0001.
(E) Extracellular acidification rate (ECAR) of the culture media representing glycolytic activity. Without glucose: p = 0.0457; with glucose: p = 0.000552; glycolytic
reserve: p < 0.0001.
(F) Cell respiration (OCR) against glycolysis (ECAR) WT versus Mut and mutator treatments: p < 0.0001.
(G) OCR in the antioxidant-treated mutator cells. Basal respiration and ATP production in NAC: p < 0.0001; maximal respiration and spare capacity in MitoQ:
p < 0.0001.
Data represent two (treated) or three (untreated) independent experiments and are represented as mean ± SEM. See also Figure S3 for glucose dependence and
fibroblast data.coverage per group was 11,250 (Table S1; NCBI SRA database;
project SRP056999). Both mutator and WT mtDNA showed
similar sequencing coverage throughout mtDNA (Figure 5A),
indicating absence of large-scale mtDNA deletions in mutator
cells.CeMutation frequencies were calculated per every nucleotide
position, and positions showing variation in >1% of all mtDNA
copies were considered variable (Figure 5B). Mutators showed
an increase in variable mtDNA sites in all cell types, and this
became increasingly pronounced the longer the cells werell Reports 11, 1614–1624, June 16, 2015 ª2015 The Authors 1619
Figure 5. Mutator Cells Show Increased mtDNA Point Mutations,
which Are Selected against during iPSC Culture
(A) Sequence coverage for the mtDNA samples across the mtDNA molecule.
(B) Number of variable sites (variation frequency per position >1%). WT versus
Mut; fibroblasts (Fb): p = 0.0615; iPSC early: p = 0.0022; iPSC late: p = 0.0013;
iPSC-derived fibroblasts (20Fb): 0.0026. Reprogramming (Fb versus iPSC
early); Mut: p = 0.0021. iPSC culture (early versus late); WT: 0.038. Differen-
tiation (late versus 20Fb; paired t test of three clones): p = 0.0020.
(C) Distribution of variation in iPSCs between different regions in mtDNA
(percentage of positions showing variation >1%). WT RC protein-coding
genes: p = 0.035.
Data represent one independent experiment and are represented as
mean ± SEM. See also Table S1 for coverage data.kept in culture (Figure 2B), consistent with constant mutagen-
esis. The mutation loads in the fibroblasts were partially due to
maternal inheritance from the heterozygote females, similar be-
tween mutator and WT cells, because littermates were used as
WT controls. To minimize maternal contribution, we maintain
mutators through male mice and use only one generation of
young heterozygous females to produce the study groups.
mtDNAmutation load increased during reprogramming in both
mutators and WTs, whereas, during iPSC culture, variable sites
decreased in WT and also in mutator cells (Figure 5B), despite
continuous mutagenesis. Upon differentiation of iPSCs to sec-
ondary fibroblasts, variable sites in mutators increased again,
evident already after 2 weeks of differentiation (Figure 5B). These
results suggest a negative selection pressure against mtDNA
mutations in iPSCs.
To identify whether the selection during iPSC culture was
random, we analyzed how different types of mutations behaved.
In WT cells, mutations affecting the RC protein-coding genes
showed significant negative selection and rRNA gene variants
showed a similar tendency, whereas mutations affecting tRNA
genes were not selected against (Figure 5C). In mutator cells,
similar tendencies were seen, but the pattern did not reach sig-
nificance, likely due to the strong background from the constant
random generation of new mutations.
These data demonstrate that iPSCs show strong functional
selection against mtDNA mutations in genes encoding the RC1620 Cell Reports 11, 1614–1624, June 16, 2015 ª2015 The Authorscomplex subunits, with little selection pressure directed toward
tRNA mutations.
DISCUSSION
ROS is a collective term for highly reactive molecules generated
upon incomplete reduction of oxygen. They aremostly known for
causingoxidative damagebut are increasingly recognized toalso
function as important intracellular signaling molecules (Hama-
naka and Chandel, 2010; Suda et al., 2011). This signaling has
been suggested to operate through covalent modifications in
the target proteins or through specific sensors able to detect
and directly respond to intracellular changes through redox-
based mechanisms (D’Autre´aux and Toledano, 2007; Nathan,
2003). The physiological ROS signals, not associated with oxida-
tivedamage, are especially important for stemcell functions, pro-
moting progenitor cell proliferation (Le Belle et al., 2011; Suda
et al., 2011). mtDNA mutator mice manifest a severe early onset
SSC dysfunction, explaining the progeroid phenotype of these
mice (Ahlqvist et al., 2012; Chen et al., 2009; Norddahl et al.,
2011). We show here that iPSC reprogramming and PSC self-
renewal—stemness—are sensitive to subtle changes in ROS
signaling, originating from mtDNA mutagenesis. Two different
antioxidants, NAC andMitoQ, efficiently rescued the reprogram-
ming and self-renewal defects in mutator PSCs, indicating that
reprogramming to stem cells, as well as stem cells themselves,
are sensitive to antioxidants. The mechanisms of action are
different for NAC and MitoQ. NAC increases cellular glutathione
pool and enhances processing of H2O2 in the cytosol, whereas
MitoQacts upstream,probably by sequestering orpreventing su-
peroxide production within mitochondria, before it forms H2O2.
Intense research aims to find factors important for reprogram-
ming efficiency. Vitamin C, a cofactor with both antioxidant and
pro-oxidant properties, was found to improve reprogramming
efficiency (Esteban et al., 2010), raising the question whether
ROS contribute to reprogramming. However, Vitamin C has a
multitude of different functions, with a potential role in histone
demethylation as well as DNA repair (Mandl et al., 2009), and
therefore, the role of ROS in reprogramming remained open (Qi
et al., 2015)—partially also due to lack of reliable methods to
detect subtle changes in ROS levels. We demonstrate here,
utilizing a mitochondria-targeted H2O2 reactive probe and ratio-
metric mass spectrometry (Cocheme´ et al., 2011, 2012), that
mtDNA mutagenesis induces a subtle increase in mitochondrial
H2O2, the rescue of which by MitoQ completely restores the re-
programming defect, whereas NAC rescued the defect partially.
These data strongly suggest that mitochondria-derived H2O2
inhibits reprogramming efficiency. These antioxidants did not,
however, improve WT reprogramming efficiency, suggesting
that downregulation of mitochondrial respiration together with
endogenous cellular ROS scavengerswere sufficient tominimize
H2O2 production upon reprogramming. The antioxidants did not
ameliorate the growth defect of the mutator iPSCs or EBs, which
was similar to that previously reported in mutator NSCs (Ahlqvist
et al., 2012). This growth defect may be contributed by various
anabolic functions of mitochondria beyond ATP production,
but not by ROS signaling, indicating separate signaling for
growth and stemness in iPSCs.
Our results indicate that the importance of ROS signaling in
stem cells makes these cells also sensitive to antioxidants,
with potential dose-dependent toxicity. MitoQ significantly
impaired self-renewal of WT iPSCs at concentrations that were
well tolerated by fibroblasts or differentiated neuronal cells, as
well as the cells undergoing reprogramming, suggesting that
the cellular metabolism of the latter is still partially fibroblast-
like. In mouse embryos in vivo, doses improving mutator HPC
phenotypes severely compromised NSC viability, raising the
question of MitoQ safety for NSCs. MitoQ comprises ubiqui-
none, the antioxidant moiety of coenzyme-Q10, covalently linked
to lipophilic TPP cation, which enables MitoQ to cross mem-
branes efficiently and to accumulate several-hundred-fold within
mitochondria in response to the organelle’s membrane potential
(Murphy and Smith, 2007). Different tissues have been reported
to accumulate MitoQ with different efficiencies (Rodriguez-
Cuenca et al., 2010), making dose control for a specific cell
type, or its mitochondria, difficult. A range of literature reports
MitoQ treatment effects in many kinds of pathologies, in rodent
models and also in human trials, with no reported in vivo toxicity
in rodents following 4- or 5-month administration or in humans
following 1 year’s administration (Smith and Murphy, 2010).
For example, MitoQ delayed progression of cardiac damage
and various types of neurodegenerative symptoms, including
ALS and Alzheimer’s disease, in animal models (Manczak
et al., 2010; Miquel et al., 2014; Yancey et al., 2015). However,
a human trial for Parkinson’s disease found no effect of MitoQ
for progression of the disease (Snow et al., 2010). No previous
data exist on the effects of MitoQ on stem cells. Our results
show that the therapeutic window of MitoQ for stem cells is nar-
row. In contrast, high concentrations of NAC did not show
toxicity, which suggests to a specific feature for MitoQ and
potentially for other mitochondria-accumulating antioxidants.
TPP alone did not induce toxicity in NSCs in vivo, indicating
that the high concentrations of TPP cations in mitochondria,
which may lead to non-specific disruption of mitochondrial
function (Murphy and Smith, 2007), did not explain the toxicity
of MitoQ to NCSs. Our results show that special attention should
be paid to antioxidant and redox effects on the stem cell
compartment, especially when developing mitochondria-tar-
geted antioxidants.
We found that mutator iPSCs actively downregulated mito-
chondrial respiration and showed a combined RC deficiency,
which did not severely compromise their highly glycolytic energy
metabolism or viability in high-glucose growth conditions. The
enforced glycolysis was specific for mutator iPSC, and both
MitoQ and NAC restored the metabolism to the bivalent WT
mode, typical for mouse PSCs (Zhou et al., 2012). These data
indicate that, even upon RC dysfunction and mtDNA mutagen-
esis, the metabolic shift to glycolysis and RC deficiency were
partially reversible and mediated by ROS signaling. We propose
that a glycolytic shift in stem cells exists as a protective response
to maintain sensitivity to ROS signals.
The antioxidant rescue of RC protein amounts, restoring com-
plex I and complex III to WT level, suggest that the major ROS
producers of RC may be actively degraded as a response to
mitochondrial mutagenesis. Complex I deficiency is a common
finding in several mitochondrial disorders (Kirby et al., 1999),Ceand recent evidence suggests that CI deficiency in disease can
also be a physiological response to metabolic insult. In patients
withmtDNAmaintenance disorders, also including PolG defects,
the degree of CI deficiency in the brain did not correlate with the
severity—or even presence—of the brain manifestations (Palin
et al., 2013). Furthermore, in iPSC-derived neurons carrying a
pathological mitochondrial tRNA mutation, CI was enriched in
autophagosomes prior to development of CI deficiency (Ha¨ma¨-
la¨inen et al., 2013). The current findings support this degradation
to be active, mediated by ROS, and partially rescued by antiox-
idant treatment.
mtDNA mutations accumulating in iPSCs could contribute to
their metabolic phenotypes. The reprogramming process itself
can contribute to mutation rates: nuclear genomic mutations
arise during reprogramming and are selected against during
subsequent culture (Hussein et al., 2011). iPSCs have also
been reported to carry mtDNA mutations (Prigione et al., 2011).
Whether these arise during reprogramming or represent
changes that were present at low frequency in the parental cells
and whether they are selected against during iPSC culture is
unknown. We found that both mutator and WT cells showed an
increase in mtDNA mutation load during reprogramming, sug-
gesting that, similarly to nuclear DNA, also mtDNA mutations
arise during the reprogramming process. However, whereas
the mtDNA mutation loads were consistently higher in mutator
cells than in WT cells, no specific mutations were present at
high enough frequencies to account for the different characteris-
tics between WT and mutator cells. The high proliferation rate of
PSCs makes them particularly prone to generate mitochondrial
mutations by replication errors. However, during in vitro culture,
the WT iPSCs were able to eliminate most of their mtDNA muta-
tions and the mutation loads did not increase during mutator
iPSC culture either. This was unexpected, as the exonuclease-
defective mtDNA polymerase should frequently generate new
mutations. These results point to a strong purifying selection
against mtDNA mutations in iPSCs. Such selection has been
described to occur in oocyte development of mutator mice,
with rapid elimination of especially the non-synonymous
changes in the protein-coding mitochondrial genes in the so-
called mtDNA bottleneck (Stewart et al., 2008). Indeed, iPSCs
showed a similar preference to select against protein-coding
gene mutations and to a lesser extent also against rRNA gene
variants. Consistently, previous reports of human iPSCs gener-
ated from patients with mtDNA mutations showed that both
mitochondrial tRNA and protein-coding genemutations survived
through reprogramming, but only tRNA mutations maintained
stable heteroplasmy, whereas RC protein-coding gene mutation
was purged upon iPSC culture (Folmes et al., 2013; Ha¨ma¨la¨inen
et al., 2013). These results suggest that the purifying selection of
germ cells could be a general feature of stem cells.
In conclusion, we demonstrate that mtDNA mutations can
reduce reprogramming efficiency of somatic cells and lead to
stemness defects via ROS-mediated signaling. Antioxidants
can cure these defects, and mitochondrial-targeted MitoQ was
very effective in rescue but also showed toxic effects. Antioxi-
dants are common dietary supplements worldwide. Little is,
however, known of their cell-type-specific effects. Our data indi-
cate that a therapeutic dose may vary considerably between cellll Reports 11, 1614–1624, June 16, 2015 ª2015 The Authors 1621
types: a dose that may rescue pathology in one tissue may
severely challenge function in another. An effect on NSC pool
may remain undetected for years. Our data implicate the
need of dose-effect studies of antioxidants on SSC pools to
establish their safety as nutritional supplements or therapeutic
agents—especially in the case of antioxidants accumulating
into mitochondria.
EXPERIMENTAL PROCEDURES
Establishment of Fibroblast Cultures
All animal experimentation was approved by the Ethical Review Board of
Finland. Mice with a knockin inactivating mutation (D257A) in the exonuclease
domain of DNA polymerase gamma (Kujoth et al., 2005) were used. For antiox-
idant supplementation, the mice were given either NAC (1 mg/ml; Sigma-Al-
drich), MitoQ (0.75 mg/ml; provided by M.P.M.) or lipophilic dTPP without
ubiquinone bound to cyclodextrin (0.48 mg/ml; equivalent to 0.75 mg/ml
MitoQ) in the drinking water of the females throughout pregnancy. Fibroblasts
were extracted from treated and non-treated E13.5–14.5 embryos using stan-
dard protocol. For in vitro culture, the medium was supplemented with either
100 mMNAC or 10–250 nMMitoQ throughout all experiments unless otherwise
stated.
Characterization of Fibroblasts
To analyze growth of the fibroblasts, the cells were grown in Cell-IQ live-cell-
imaging incubator. Growth curves were generated using Cell-IQ Analyzer
software (CM Technologies). To assess the transfection efficiency, a piggybac
transposon-based GFP plasmid was electroporated together with the pCyL43
transposase using the same setting as for the reprogramming plasmids. Stably
transfected cells were analyzed by FACS for the proportion of GFP-positive
cells 1 week later. For the clonality assays, the cells were plated on clonal di-
lutions and the number of colonies was counted 2 weeks later.
Generation and Culture of iPSCs
iPSCs were generated using transposon-mediated gene transfer (Woltjen
et al., 2009, 2011). The transfections were done using Neon electroporator
(Invitrogen; one pulse; 30 mS; 1,300 V) with 5 mg of DNA and 5 3 105 cells
per electroporation. The culture media was supplemented with 1 mg/ml of
doxycycline on the next day. For reprogramming in different oxygen tensions,
the electroporations were split on two separate plates: one cultured in 4% O2
(Biospherix ExVivo chamber) whereas the other in normal room air of around
20% O2. To assess the reprogramming efficiency, plates were stained on
day 14 for alkaline phosphatase (AP) activity (Vector Red Alkaline Phosphate
substrate kit). For clonality assays, cells were plated on day 0 on clonal
dilutions and stained on day 7. The number of AP-positive clones was counted
using ImageJ 1.44o software (NIH).
The screening for transgene silencing was done by lacZ staining (Woltjen
et al., 2009, 2011), and karyotyping was done commercially (Chrombios).
The iPSC growth curves were done by plating 23 104 cells per well and count-
ing the cell number on 4 consecutive days.
PCR and RT-PCR
DNA was purified from cells by phenol-chloroform extraction, and total RNA
was purified using Trizol reagent (Invitrogen). Reverse transcription was per-
formed using MMLV-RTase and random hexamers (Promega). Quantitative
RT-PCR was performed using the CFX96 platform (Bio-Rad) and Dynamo
Flash SYBRgreen qPCR kit (Thermo Scientific). All qPCR assays were per-
formed twice and in triplicates. Relative gene expression levels were normal-
ized against b-actin.
In Vitro Differentiation
EBs were generated by hanging drop method. The iPSCs were trypsinized to
single cells, and drops of media with 200 cells/drop were hung on petri dish
covers for 3 days, after which the EBs were cultured in suspension culture
for an additional week and LIF was withdrawn from the EB culture medium.1622 Cell Reports 11, 1614–1624, June 16, 2015 ª2015 The AuthorsSecondary fibroblastswere generated bywithdrawing LIF from the cultureme-
dium and inducing differentiation with 1 mM retinoic acid for 6 days. After this,
the cells were passaged and cultured for 8 additional days in fibroblast media.
At this point, all cells were flat and no cells with ESC-likemorphology were pre-
sent in the cultures.
Teratoma Formation
For teratoma formation, about 2 3 105 iPSCs were injected intratesticularly
into NMRI nude mice (Scanbur). After 6 weeks, tumors were collected, fixed
overnight in 4% paraformaldehyde (PFA), embedded in paraffin, and stained
with H&E. The experimental animal welfare committee of the District Govern-
ment of Southern Finland approved the animal experiments.
Immunofluorescence and FACS
For immunofluorescence, cells were fixed with 4% PFA. SSEA1, FACS ana-
lyses were done on live cells. Primary antibodies were against SSEA1 (IF:
1:250, ab16285, Abcam; FACS: 1:100, 90230, Millipore), Nanog (1:250;
ab80892; Abcam), Tuj-1 (1:500; Nordic BioSite), and GFAP (1:1,000; Chemi-
con). Nuclei were stained with DAPI. Flow cytometry was run using BD Accuri
C6 Flow Cytometer and analyzed using the Accuri C6 Analysis software.
BrdU Incorporation and Apoptosis Assays
To determine the proliferation rate, iPSCs were incubated in 10 mM BrdU (BD
PharMingen) for 15 min, fixed with ethanol, denatured with 1 M HCl, and per-
meabilized using 0.5%Triton X-100. Cells were stained usingmonoclonal anti-
BrdU antibody (1:4; Becton Dickinson). Cells were run using BD Accuri C6
Flow Cytometer and analyzed using the Accuri C6 Analysis software.
Apoptosis was analyzed by Annexin V-FITCH Apoptosis Detection kit (BD
PharMingen) according to the manufacturer’s instructions.
MitoP/MitoB Mass Spectrometry for ROS Measurement
A mitochondria-targeted ratiometric mass spectrometry probe MitoB was
used to measure hydrogen peroxide in the mitochondrial matrix as published
earlier (Cocheme´ et al., 2011, 2012). Briefly, the cells were incubated with 5 mM
MitoB together with 50 U/ml catalase for 6 hr, after whichmedia was collected,
snap frozen, and processed for mass spectrometry.
SSC Analysis
Isolation and analysis of NSCs and HSCs were performed as previously
described (Ahlqvist et al., 2012; Piltti et al., 2006).
Analysis of the RC Complexes by Western Blot
Primary antibodies were against COX1 (1:500; M404; Mitosciences),
CI-NDUFA9 (1:2,000; ab14713; Abcam), CII-70kD (1:10,000; MS204; Mito-
sciences), CIII-UQCRC2 (1:2,500; ab14745; Abcam), CV-a (1:1,000; MS507;
Mitosciences), b-Actin (1:2,000; SC1616; Santa Cruz Biotechnology), and
TOM20 (1:500; SC11415; Santa Cruz Biotechnology). Western blot analysis
was done from total protein lysates according to standard protocol.
COX Activity
IPSCs were grown on gelatin in chamber glasses and washed three times with
PBS + Mg + Ca. The cells were incubated in preincubation medium (10% su-
crose and 0.03% cobalt chloride in 50 mM Tris-HCl [pH 7.6]) for 15 min at RT.
Cells were washed with sodium phosphate + sucrose, followed by incubation
with cytochrome C, DAB hydrochloride, and catalase at + 37C for 1 hr. After
that, cells were washed and forwarded to microscopy.
Metabolism Assays
Cell metabolism was analyzed by Seahorse XFe96 extracellular flux platform
using the XF Cell Mito Stress test and XF Glycolysis Stress Test kits (Seahorse
Bioscience). Data were normalized against total protein amounts per well
(analyzed by Bradford assay) and analyzed usingWave2.0 software (Seahorse
Bioscience).
Next-Generation Sequencing
Genomic DNA concentrations were measured with Qubit BR dsDNA kit (Life
Technologies). mtDNA was amplified from the genomic DNA using REPLI-g
Mitochondrial DNA Kit (QIAGEN). After enrichment, the amplified mtDNA sam-
ples were processed to Illumina-sequencing-compatible libraries with Nextera
DNA sample preparation kit (Illumina). The mtDNA concentrations were
measured with Qubit dsDNA kit for Nextera tagmentation reaction. The reac-
tion volume in Nextera tagmentation and amplification steps was 20 ml, and af-
ter both steps, the libraries were purified with EdgeBio Performa V3 96-Well
Short Plate (Edge BioSystems). After amplification, the libraries were incu-
bated with 4 ml of EdgeBio SOPE Resin and purified with EdgeBio Performa
plates. After purification, the samples with different index tags were pooled
together (2 ml each) and concentrated with DNA Clean & Concentrator-5
(Zymo Research). The sequencing-ready libraries were quantitated with
Agilent 2100 Bioanalyzer High Sensitivity kit (Agilent). The libraries were
sequenced in Illumina HiSeq system.
Statistical Analysis
Statistical analysis was performed when each group had at least three sam-
ples with unpaired t test (GraphPad Prism software). p < 0.05 was considered
significant; *p < 0.05; **p < 0.005; ***p < 0.0005. All results are presented as
mean ± SEM.
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